Overview

This study is to evaluate the efficacy and safety of JAB-21822 monotherapy in adult participants with KRAS G12C mutated pancreatic cancer

Eligibility

Inclusion Criteria:

• Histopathologically or cytologically confirmed pancreatic cancer with KRAS p.G12C mutation identified through molecular testing.
• Previously progressed on or after gemcitabine-based and/or FOFIRINOX/mFOFIRINOX chemotherapy, no more than 3 lines of prior systemic therapies. Participants with disease recurrence during or within 6 months after adjuvant therapy can be included.
• Participants with MSI-H/dMMR must experience anti-PD-1 therapy.

Exclusion Criteria:

• Previously received a KRAS G12C inhibitor.
• History of interstitial lung disease, non-infectious pneumonia, or uncontrolled lung disease (including pulmonary fibrosis, acute lung disease, etc.).
• Uncontrolled pleural effusion, pericardial effusion, or ascites.
• Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms calculated from 3 electrocardiograms.
• Use of a drug with known risk of torsades de points (TdP) within 14 days prior to the first dose.
• Cannot discontinue a proton pump inhibitor (PPI) or H2 receptor blocker within 3 days or 5 half-lives (whichever is longer) prior to the first dose.